These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2929497)

  • 1. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood.
    Bode AP; Eick L
    Am J Clin Pathol; 1989 Apr; 91(4):430-4. PubMed ID: 2929497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
    Bode AP; Castellani WJ; Hodges ED; Yelverton S
    Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity.
    Bode AP; Lust RM
    Thromb Res; 1994 Mar; 73(5):285-300. PubMed ID: 7517074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heparin, platelets, activated platelets, platelet fragments, and hematocrit on activated clotting time.
    Girardi L; Sudi K; Muntean W
    Artif Organs; 2000 Jul; 24(7):507-13. PubMed ID: 10916060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet involvement in the activated coagulation time of heparinized blood.
    Moorehead MT; Westengard JC; Bull BS
    Anesth Analg; 1984 Apr; 63(4):394-8. PubMed ID: 6367544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time measurement of free thrombin: evaluation of the usability of a new thrombin assay for coagulation monitoring during extracorporeal circulation.
    Krajewski S; Krauss S; Kurz J; Neumann B; Schlensak C; Wendel HP
    Thromb Res; 2014 Mar; 133(3):455-63. PubMed ID: 24359968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACTIVATION OF COAGULATION AND FIBRINOGEN LOSS AFTER USING AN EXTRACORPOREAL CIRCULATION.
    BLOOM AL
    J Clin Pathol; 1963 Nov; 16(6):558-68. PubMed ID: 14076375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation time of blood heparinized in vitro: correlation of results with those of the heparin tolerance test.
    HAGEDORN AB; BARKER NW
    J Lab Clin Med; 1947 Sep; 32(9):. PubMed ID: 20267267
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of low affinity platelet factor 4 in frozen and thawed human platelets by the newly developed enzyme immunoassay system.
    Shimizu T; Noda Y; Goto S; Morishima Y; Hasegawa I; Fukuda T; Kato K
    Tohoku J Exp Med; 1984 Apr; 142(4):453-60. PubMed ID: 6377582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of heparin on the early stages of blood coagulation.
    O'BRIEN JR
    J Clin Pathol; 1960 Mar; 13(2):93-8. PubMed ID: 14428016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
    Mabry CD; Thompson BW; Read RC; Campbell GS
    Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of procoagulant phospholipid interfering in tests for lupus anticoagulant.
    Exner T; Low J
    Thromb Res; 2004; 114(5-6):547-52. PubMed ID: 15507290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique.
    Ichikawa J; Hagihira S; Mori T; Kodaka M; Nishiyama K; Ozaki M; Komori M
    J Anesth; 2016 Dec; 30(6):923-928. PubMed ID: 27502398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.